PAVmed Inc. (NASDAQ:PAVM) gapped down prior to trading on Monday . The stock had previously closed at $8.14, but opened at $7.62. PAVmed shares last traded at $7.59, with a volume of 5,195 shares.
Several analysts have weighed in on the company. Zacks Investment Research cut PAVmed from a “hold” rating to a “sell” rating in a report on Wednesday, August 18th. Cantor Fitzgerald reiterated an “overweight” rating on shares of PAVmed in a research report on Friday, July 9th. Finally, Maxim Group reissued a “buy” rating and issued a $8.00 price target on shares of PAVmed in a research note on Friday, August 13th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $7.50.
The stock has a market capitalization of $684.93 million, a P/E ratio of -14.69 and a beta of 0.31. The firm has a 50-day moving average price of $6.97 and a 200 day moving average price of $5.77.
Several institutional investors have recently made changes to their positions in PAVM. Royal Bank of Canada grew its holdings in shares of PAVmed by 89.2% during the 1st quarter. Royal Bank of Canada now owns 5,593 shares of the company’s stock valued at $25,000 after purchasing an additional 2,637 shares during the last quarter. Allred Capital Management LLC purchased a new stake in PAVmed during the first quarter valued at about $26,000. Perigon Wealth Management LLC bought a new position in shares of PAVmed during the first quarter valued at about $44,000. SG Americas Securities LLC purchased a new position in shares of PAVmed in the first quarter worth about $49,000. Finally, Victory Capital Management Inc. bought a new stake in shares of PAVmed in the 1st quarter valued at about $56,000. 24.81% of the stock is owned by institutional investors.
About PAVmed (NASDAQ:PAVM)
PAVmed, Inc is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: GI Health, Minimally Invasive Interventions, Infusion Therapy, and Emerging Innovations. The GI health division comprises of EsoGuard esophageal DNA laboratory developed test, EsoCheck Esophageal Cell Collection Device, and EsoCure Esophageal Ablation Device with Caldus technology.
Recommended Story: What are the disadvantages of after-hours trading?
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.